230 related articles for article (PubMed ID: 35550553)
21. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
[TBL] [Abstract][Full Text] [Related]
22. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
23. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Mullinax JE; Hall M; Prabhakaran S; Weber J; Khushalani N; Eroglu Z; Brohl AS; Markowitz J; Royster E; Richards A; Stark V; Zager JS; Kelley L; Cox C; Sondak VK; Mulé JJ; Pilon-Thomas S; Sarnaik AA
Front Oncol; 2018; 8():44. PubMed ID: 29552542
[TBL] [Abstract][Full Text] [Related]
24. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
25. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
26. Analysis of T cell receptor alpha beta variability in tumor-infiltrating lymphocytes in primary and metastatic melanoma.
Zeuthen J; Birck A; Straten PT
Arch Immunol Ther Exp (Warsz); 1995; 43(2):123-33. PubMed ID: 8744727
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB; Bounova G; Kerzeli I; Anzar I; Simnica D; Aamdal E; Guren T; Clancy T; Mezheyeuski A; Inderberg EM; Mangsbo SM; Binder M; Hovig E; Gaudernack G
J Transl Med; 2022 Sep; 20(1):419. PubMed ID: 36089578
[TBL] [Abstract][Full Text] [Related]
29. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
Fortman D; Karunamurthy A; Hartman D; Wang H; Seigh L; Abukhiran I; Najjar YG; Pantanowitz L; Zarour HM; Kirkwood JM; Davar D
Oncologist; 2024 Apr; ():. PubMed ID: 38655867
[TBL] [Abstract][Full Text] [Related]
30. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
Page DB; Yuan J; Redmond D; Wen YH; Durack JC; Emerson R; Solomon S; Dong Z; Wong P; Comstock C; Diab A; Sung J; Maybody M; Morris E; Brogi E; Morrow M; Sacchini V; Elemento O; Robins H; Patil S; Allison JP; Wolchok JD; Hudis C; Norton L; McArthur HL
Cancer Immunol Res; 2016 Oct; 4(10):835-844. PubMed ID: 27587469
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
[TBL] [Abstract][Full Text] [Related]
32. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
33. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS; Wolchok JD; Schadendorf D; Larkin J; Long GV; Qian X; Saci A; Young TC; Srinivasan S; Chang H; Tang H; Wind-Rotolo M; Rizzo JI; Jackson DG; Ascierto PA
Cancer Immunol Res; 2021 Oct; 9(10):1202-1213. PubMed ID: 34389558
[TBL] [Abstract][Full Text] [Related]
34. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
35. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
Adegoke NA; Gide TN; Mao Y; Quek C; Patrick E; Carlino MS; Lo SN; Menzies AM; Pires da Silva I; Vergara IA; Long G; Scolyer RA; Wilmott JS
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865395
[TBL] [Abstract][Full Text] [Related]
36. Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8
Gokuldass A; Draghi A; Papp K; Borch TH; Nielsen M; Westergaard MCW; Andersen R; Schina A; Bol KF; Chamberlain CA; Presti M; Met Ö; Harbst K; Lauss M; Soraggi S; Csabai I; Szállási Z; Jönsson G; Svane IM; Donia M
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198174
[No Abstract] [Full Text] [Related]
37. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT; Rohaan MW; Jedema I; Kessels R; Stegeman W; Scheepmaker W; Nuijen B; Nijenhuis C; Lindenberg M; Borch TH; Monberg T; Donia M; Marie Svane I; van Harten W; Haanen J; Retel VP
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38531663
[TBL] [Abstract][Full Text] [Related]
38. Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges.
Indini A; Massi D; Pirro M; Roila F; Grossi F; Sahebkar A; Glodde N; Bald T; Mandalà M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):477-490. PubMed ID: 35752398
[TBL] [Abstract][Full Text] [Related]
39. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
Pistillo MP; Carosio R; Grillo F; Fontana V; Mastracci L; Morabito A; Banelli B; Tanda E; Cecchi F; Dozin B; Gualco M; Salvi S; Spagnolo F; Poggi A; Queirolo P
Clin Immunol; 2020 Jun; 215():108428. PubMed ID: 32344017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
